Contact this trialFirst, we need to learn more about you.
Checkpoint Inhibitor
mRNA Vaccine + Immunotherapy for Melanoma
Recruiting1 awardPhase 2
Nashville, Tennessee
This trial will test whether adding the immunotherapy drug, mRNA-4157, to standard of care, pembrolizumab, will improve recurrence free survival in people with high risk melanoma who have had surgery to remove the tumor.
Fill-in a few details and create your profileHaving a profile will help us send you recommended trials and speed up your application in the future.
We will keep your details privateWe won’t share unless you give us permission. By completing this form you agree to our privacy policy
Get in touch with the study teamWe’ll send your responses to the study team and help you to setup your first screening. This is not the start of informed consent. Screening happens between you and the trial.